SCHEMBL13729217

SCHEMBL13729217

Cc1cc(CNC(=O)O)c[nH]c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ERCC1 P07992 1/20 0.40
ERCC4 Q92889 1/20 0.40
BRD4 O60885 1/20 0.39
CYP2C19 P33261 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
TSHR P16473 1/20 0.39
DAO P14920 5/20 0.37
ALDH2 P05091 2/20 0.36
MMP13 P45452 1/20 0.36
MCL1 Q07820 1/20 0.36
NR1H4 Q96RI1 2/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12217552 0.74 DAO (0.40) KDM4EALDH1A1BRD4DAOMEN1
SCHEMBL20670337 0.72 DAO (0.39) KDM4EBRD4DAOPKM
SCHEMBL22501787 0.71 L3MBTL1 (0.45) KDM4ECYP2C19CYP1A2CYP2D6CYP2C9
SCHEMBL14466317 0.71 DAO (0.38) KDM4EBRD4DAO
SCHEMBL18933659 0.71 DAO (0.45) ALDH1A1BRD4DAO
SCHEMBL585949 0.71 NR1H4 (0.58) ALDH1A1HPGDCYP2C19CYP1A2CYP2D6
SCHEMBL24666071 0.70 DAO (0.38) KDM4EBRD4DAO
SCHEMBL18171803 0.69 DAO (0.38) KDM4EHPGDHSD17B10ERCC1ERCC4
SCHEMBL13616964 0.69 TTK (0.47) ALDH1A1BRD4CYP1A2CYP2D6TSHR
SCHEMBL24664734 0.69 DAO (0.39) BRD4DAOMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2704712-A1 ISOXAZOLINES AS THERAPEUTIC AGENTS AbbVie Inc. (US) 2014-03-12 EP disclosed
WO-2012151158-A1 ISOXAZOLINES AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2012-11-08 WO disclosed